FILE PHOTO: AstraZeneca’s cancer medicine Enhertu, a drug developed jointly with Japan’s Daiichi Sankyo, is pictured in an undated handout image obtained by Reuters on June 27, 2022. AstraZeneca/Handout via REUTERS
AstraZeneca said Monday that a mid-stage trial of its cancer drug Enhertu, co-developed with Daiichi Sankyo, showed positive results across multiple HER2-expressing advanced solid tumors in heavily pre-treated patients.
The ongoing DESTINY-PanTumor02 Phase II trial is assessing the efficacy and safety of Enhertu in patients with locally advanced or metastatic previously treated solid tumors that are not eligible for curative therapy, including cervical, ovarian, pancreatic, and rare cancers.
“Enhertu has already demonstrated its potential to improve outcomes for patients with HER2-targetable breast, gastric and lung cancers, and these positive initial results in other tumor settings with significant unmet need are very encouraging,” Cristian Massacesi, AstraZeneca’s chief medical officer and oncology chief development officer, said in a statement.
RELATED STORIES
Two AstraZeneca drugs get EU backing for treatment of some breast cancers
Bristol Myers sues AstraZeneca over cancer-treatment patents